Celyad Oncology SA (EBR:CYAD)

Market Cap	17.46M -23.4%
Revenue (ttm)	186.00K +158.3%
Net Income	-6.46M
EPS	-0.16
Shares Out	44.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,759
Average Volume	278,470
Open	0.3610
Previous Close	0.3900
Day's Range	0.3600 - 0.3820
52-Week Range	0.1600 - 0.6500
Beta	0.72
RSI	58.92
Earnings Date	Apr 2, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 19
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.